BioXcel Therapeutics

BioXcel Therapeutics

BioXcel Therapeutics was incorporated in 2017 as a wholly owned subsidiary of BioXcel Corporation before its separation, with Vimal Mehta serving as CEO from inception. The company applies artificial intelligence to the repurposing of established drugs for new neurological and oncological indications, a methodology that constructs clinical candidates from molecules with existing human safety data. The firm raised approximately $80 million during its initial public offering on the Nasdaq in March 2018. Its primary development focus has centered on Igalmi, a sublingual dexmedetomidine film for agitation in schizophrenia and bipolar disorder, and BXCL701, an immune-oncology candidate. BioXcel's core strategy involves deploying a proprietary AI platform across central nervous system conditions like Alzheimer's agitation, major depressive disorder, and agitation associated with autism spectrum disorder. The company maintains a commercial infrastructure that launched a hospital-focused sales force for Igalmi's approval for acute treatment of agitation in April 2022. The pipeline is augmented by immuno-oncology programs evaluating BXCL701 in combination with KEYTRUDA for small cell lung cancer and other solid tumors, with mid-stage trial data reported in 2023. The firm's model combines commercial-stage neuroscience product revenue with early oncology clinical investments. In January 2025, BioXcel implemented a strategic restructuring to prioritize commercial execution of Igalmi over early-stage neurology research, reducing headcount and external spending. Before the restructuring the company employed approximately 190 people. Its workforce historically operated from the New Haven headquarters. The company has maintained a public listing on Nasdaq under the ticker BTAI, with no disclosed adjacent private vehicles or foundation structures under common control. BioXcel Therapeutics' structural distinction lies in its commercial-presence model for an AI-originated neuroscience product — a layout that produces recurring revenue while supporting pipeline development, a posture rare among clinical-stage biotechs still dependent solely on capital markets. The restructuring of January 2025 reoriented the company toward profitability from the Igalmi franchise without external partnership support for U.S. commercialization.